Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
Cancer Medicine · 2023-03 · 12 (6) · 7077-7089
DOI: 10.1002/cam4.5506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 05.12.2022. Verfasst von Chung-Wei Su und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lenvatinib and atezolizumab plus bevacizumab(A + B) have been used for unresectable hepatocellular carcinoma (HCC) as first‐line therapy. Real‐world studies comparison of efficacy and safety in these two regimens are limited, we therefore conduct this study to investigate these issues.
Methods
We retrospectively reviewed patients received lenvatinib ( n = 46) and A + B ( n = 46) as first‐line systemic therapy for unresectable HCC in a tertiary medical center. Objective response rate (ORR), progression free survival (PFS), and overall survival (OS) were evaluated according to modified Response Evaluation Criteria in Solid Tumors (mRECIST). Inverse probability weighting (IPW) was performed for baseline clinical features balance.
Results
A total of 92 patients with median age of 63.8 year‐old, 78.3% male, 85.9% viral hepatitis infected, 67.4% BCLC stage C were enrolled. The median treatment and follow‐up duration were 4.7 months and 9.4 months, respectively. There was no significant difference in ORR (26.1% vs. 41.3%, p = 0.1226), PFS (5.9 vs. 5.3 months, p = 0.4066), and OS (not reached vs. not reached, p = 0.7128) between the lenvatinib and A + B groups. After IPW, the results of survival and response rate were also compared. Subgroup analysis suggested that using lenvatinib was not inferior to A + B in regards of PFS, including those with elder, Child‐Pugh class B, beyond up‐to‐seven, or portal vein invasion VP4 patients. Among the lenvatinib treated patients, multivariate analysis showed patients elder than 65‐year‐old was an independent predictor associated with shorter PFS (adjust HR: 2.085[0.914–4.753], p = 0.0213). The incidence rates of adverse events were similar between two groups (76 vs. 63%, p = 0.1740). Both of two regimens had similarly few impact on liver function by comparison of baseline, third month, and sixth month albumin‐bilirubin index and Child‐Pugh score.
Conclusions
The efficacy and safety of lenvatinib are similar to A + B as a first‐line systemic therapy for unresectable HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
- Department of Medical Oncology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
- Department of Medical Oncology, Tucheng Composite Municipal Hospital, New Taipei, Taiwan.
- Department of Nursing, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
ORCID-Profile: Chung-Wei Su, Wei Teng, Wen-Juei Jeng, Yi-Chung Hsieh, Chun-Yen Lin
Zitieren
APA
Su, C. W., Teng, W., Lin, P. T., Jeng, W. J., Chen, K. A., Hsieh, Y. C., Chen, W. T., Ho, M. M., Hsieh, C. H., Wang, C. T., Chai, P. M., Lin, C. C., Lin, C. Y., & Lin, S. M. (2023). Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma. Cancer Medicine, 12(6), 7077-7089. https://doi.org/10.1002/cam4.5506
Vancouver
Su CW, Teng W, Lin PT, Jeng WJ, Chen KA, Hsieh YC, et al. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma. Cancer Medicine. 2023;12(6):7077-7089. doi:10.1002/cam4.5506
BibTeX
@article{Su2023,
author = {Su, Chung-Wei and Teng, Wei and Lin, Po-Ting and Jeng, Wen-Juei and Chen, Kuei-An and Hsieh, Yi-Chung and Chen, Wei-Ting and Ho, Ming-Mo and Hsieh, Chia-Hsun and Wang, Ching-Ting and Chai, Pei-Mei and Lin, Chen-Chun and Lin, Chun-Yen and Lin, Shi-Ming},
title = {Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {6},
pages = {7077--7089},
doi = {10.1002/cam4.5506}
}
EUVIMED